What is claimed is:

1. A compound of formula (I):



(I)

wherein

R^1 is hydrogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 4-6 membered heterocycloalkyl, or 4-6 membered heteroaryl, wherein the C_1-C_6 alkyl is optionally substituted by one, two or three substituents selected from the group consisting of halogen, hydroxy, and C_1-C_3 alkoxy, further wherein the C_3-C_6 cycloalkyl, the 4-6 membered heterocycloalkyl, and the 4-6 membered heteroaryl are each independently optionally substituted by one, two or three substituents selected from the group consisting of C_1-C_3 alkyl, hydroxy, and C_1-C_3 alkoxy;

ring A is C_6-C_{10} aryl or 5-12 membered heteroaryl;

R^2 and R^5 are each independently absent, hydrogen, halogen, cyano, difluoromethyl, trifluoromethyl, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 alkoxy, -$N(R^{10})(R^{11})$, C_3-C_5 cycloalkyl, or 4-6 membered heterocycloalkyl, wherein the C_1-C_6 alkyl is optionally substituted by one, two or three substituents selected from the group consisting of halogen, hydroxy, C_1-C_6 alkoxy, and -$N(R^{12})(R^{13})$;

R^3 is absent, hydrogen, halogen, C_1-C_6 alkyl, C_2-C_6 alkynyl, C_1-C_6 alkoxy, C_3-C_7 cycloalkyl, or 3-7 membered heterocycloalkyl, wherein the C_1-C_6 alkyl and the C_1-C_6 alkoxy are each optionally substituted by one, two or three R^{14} groups, and further wherein the C_3-C_7 cycloalkyl and the 3-7 membered heterocycloalkyl are each optionally substituted by one, two or three R^{15} groups;

R^4 is absent, hydrogen, halogen, C_1-C_6 alkyl, or C_3-C_6 cycloalkyl,

wherein R^2 and R^3 or R^3 and R^4 may combine to form a C_5-C_7 cycloalkyl ring or a 5-7 membered heterocycloalkyl ring, further wherein the C_5-C_7 cycloalkyl ring and the 5-7 membered heterocycloalkyl ring are each independently optionally substituted by one, two or three R^{14} groups;

Q is absent, O, S, or NR^9;

ring B is absent, C_3-C_{10} cycloalkyl, 3-10 membered heterocycloalkyl, C_6-C_{10} aryl, or 5-12 membered heteroaryl;

R^6 and R^8 are each independently absent, hydrogen, halogen, cyano, hydroxy, difluoromethyl, trifluoromethyl, C_1-C_3 alkyl, C_1-C_3 alkoxy, or C_3-C_5 cycloalkyl, wherein the C_1-C_3 alkyl is optionally substituted by hydroxy, difluoromethyl, trifluoromethyl, C_1-C_3 alkoxy, or C_3-C_5 cycloalkyl;

R^7 is


,

,

,

,

,

or

;

G is absent when the attachment point of R^7 on ring B is a nitrogen atom, and G is $-NR^{18}-$ when ring B is absent or when the attachment point of R^7 on ring B is a carbon atom;

R^9, R^{12} and R^{13} are each independently hydrogen or C_1-C_3 alkyl;

R^{10} and R^{11} are each independently hydrogen or C_1-C_6 alkyl; or R^{10} and R^{11} together with the nitrogen to which they are attached, may combine to form a 4-7

membered heterocycloalkyl ring, when R^{10} and R^{11} are each C_1-C_3 alkyl, wherein the 4-7 membered heterocycloalkyl ring formed is optionally substituted by one, two, three or four R^{15} groups;

each R^{14} is independently halogen, cyano, C_1-C_3 alkyl, hydroxy, C_1-C_6 alkoxy, -$N(R^{19})(R^{20})$, -$CON(R^{21})(R^{22})$, or 3-7 membered heterocycloalkyl, wherein the 3-7 membered heterocycloalkyl is optionally substituted by one, two, three or four R^{15} groups;

each R^{15} is independently halogen, C_1-C_3 alkyl, hydroxy, C_1-C_6 alkoxy, -NH_2, -$NHCH_3$, or -$N(CH_3)_2$;

R^{16} and R^{17} are each independently hydrogen or C_1-C_6 alkyl, wherein the C_1-C_6 alkyl is optionally substituted by -$N(R^{23})(R^{24})$,

provided that R^{16} and R^{17} may form a C_3-C_5 cycloalkyl ring;

R^{18} is hydrogen or C_1-C_3 alkyl;

each R^{19}, R^{20}, R^{21}, R^{22}, R^{23}, and R^{24} is independently hydrogen or C_1-C_3 alkyl; and

m is 0, 1 or 2, provided that when ring B is absent, m is 2; or

a pharmaceutically acceptable salt thereof.

2. The compound or salt of claim 1, wherein R^1 is C_1-C_6 alkyl or C_3-C_6 cycloalkyl, wherein the C_1-C_6 alkyl is optionally substituted by hydroxy, further wherein the C_3-C_6 cycloalkyl is optionally substituted by C_1-C_3 alkyl.

3. The compound or salt of claim 1, wherein R^1 is methyl, ethyl, isopropyl, or tert-butyl.

4. The compound or salt of any of claims 1-3, wherein R^2 is hydrogen, methyl, difluoromethyl, or methoxy.

5. The compound or salt of any of claims 1-3, wherein R^5 is hydrogen, C_1-C_6 alkyl, or C_1-C_6 alkoxy.

6. The compound or salt of any of claims 1-3, wherein R^5 is hydrogen, methyl, or methoxy.

7. The compound or salt of any of claims 1-3, wherein R^3 is C_1-C_6 alkyl or 3-7 membered heterocycloalkyl, wherein the C_1-C_6 alkyl is optionally substituted by one or two R^{14} groups, further wherein the 3-7 membered heterocycloalkyl is optionally substituted by C_1-C_3 alkyl.

8. The compound or salt of any of claims 1-3, wherein R^3 is methyl.

9. The compound or salt of any of claims 1-8, wherein Q is absent.

10. The compound or salt of any of claims 1-8, wherein Q is O.

11. The compound or salt of any of claims 1-8, wherein Q is NR^9.

12. The compound or salt of any of claims 1-11, wherein m is 0.

13. The compound or salt of claims 1-9, wherein ring B is 3-10 membered heterocycloalkyl.

14. The compound or salt of any of claims 1-13, having formula (II):



(II)

wherein

X is CH or N;

W is CR^2 or N,

provided that one of X and W is N and X and W cannot both be N, further provided that when W is CR^2, at least one of R^3 and R^5 is hydrogen;

R^1 is hydrogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 4-6 membered heterocycloalkyl, or 4-6 membered heteroaryl, wherein the C_1-C_6 alkyl is optionally substituted by one, two or three substituents selected from the group consisting of halogen, hydroxy, and C_1-C_3 alkoxy, further wherein the C_3-C_6 cycloalkyl, the 4-6 membered heterocycloalkyl, and the 4-6 membered heteroaryl are each independently optionally substituted by one, two or three substituents selected from the group consisting of C_1-C_3 alkyl, hydroxy, and C_1-C_3 alkoxy;

R^2 and R^5 are each independently hydrogen, halogen, cyano, difluoromethyl, trifluoromethyl, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 alkoxy, $-N(R^{10})(R^{11})$, C_3-

C_5 cycloalkyl, or 4-6 membered heterocycloalkyl, wherein the C_1-C_6 alkyl is optionally substituted by one, two or three substituents selected from the group consisting of halogen, hydroxy, C_1-C_6 alkoxy, and -N(R^{12})(R^{13});

R^3 is absent, hydrogen, halogen, C_1-C_6 alkyl, C_2-C_6 alkynyl, C_1-C_6 alkoxy, C_3-C_7 cycloalkyl, or 3-7 membered heterocycloalkyl, wherein the C_1-C_6 alkyl and the C_1-C_6 alkoxy are each optionally substituted by one, two or three R^{14} groups, and further wherein the C_3-C_7 cycloalkyl and the 3-7 membered heterocycloalkyl are each optionally substituted by one, two or three R^{15} groups;

Q is absent, O, S, or NR^9;

ring B is absent, C_3-C_{10} cycloalkyl, 3-10 membered heterocycloalkyl, C_6-C_{10} aryl, or 5-12 membered heteroaryl;

R^6 and R^8 are each independently absent, hydrogen, halogen, cyano, hydroxy, difluoromethyl, trifluoromethyl, C_1-C_3 alkyl, C_1-C_3 alkoxy, or C_3-C_5 cycloalkyl, wherein the C_1-C_3 alkyl is optionally substituted by hydroxy, difluoromethyl, trifluoromethyl, C_1-C_3 alkoxy, or C_3-C_5 cycloalkyl;

R^7 is



,


,


,


,


,


or


;

G is absent when the attachment point of R^7 on ring B is a nitrogen atom, and G is $-NR^{18}-$ when ring B is absent or when the attachment point of R^7 on ring B is a carbon atom;

R^9, R^{12} and R^{13} are each independently hydrogen or C_1-C_3 alkyl;

R^{10} and R^{11} are each independently hydrogen or C_1-C_6 alkyl; or R^{10} and R^{11} together with the nitrogen to which they are attached, may combine to form a 4-7 membered heterocycloalkyl ring, when R^{10} and R^{11} are each C_1-C_3 alkyl, wherein the 4-7 membered heterocycloalkyl ring formed is optionally substituted by one, two, three or four R^{15} groups;

each R^{14} is independently halogen, cyano, C_1-C_3 alkyl, hydroxy, C_1-C_6 alkoxy, $-N(R^{19})(R^{20})$, $-CON(R^{21})(R^{22})$, or 3-7 membered heterocycloalkyl, wherein the 3-7 membered heterocycloalkyl is optionally substituted by one, two, three or four R^{15} groups;

each R^{15} is independently halogen, C_1-C_3 alkyl, hydroxy, C_1-C_6 alkoxy, $-NH_2$, $-NHCH_3$, or $-N(CH_3)_2$;

R^{16} and R^{17} are each independently hydrogen or C_1-C_6 alkyl, wherein the C_1-C_6 alkyl is optionally substituted by $-N(R^{23})(R^{24})$,

provided that R^{16} and R^{17} may form a C_3-C_5 cycloalkyl ring;

R^{18} is hydrogen or C_1-C_3 alkyl;

each R^{19}, R^{20}, R^{21}, R^{22}, R^{23}, and R^{24} is independently hydrogen or C_1-C_3 alkyl; and

m is 0, 1 or 2, provided that when ring B is absent, m is 2; or

a pharmaceutically acceptable salt thereof.

15. The compound or salt of any of claims 1-13, having formula (III):



(III)

wherein

R^1 is hydrogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 4-6 membered heterocycloalkyl, or 4-6 membered heteroaryl, wherein the C_1-C_6 alkyl is optionally substituted by one, two or three substituents selected from the group consisting of halogen, hydroxy, and C_1-C_3 alkoxy, further wherein the C_3-C_6 cycloalkyl, the 4-6 membered heterocycloalkyl, and the 4-6 membered heteroaryl are each independently optionally substituted by one, two or three substituents selected from the group consisting of C_1-C_3 alkyl, hydroxy, and C_1-C_3 alkoxy;

R^2 and R^5 are each independently hydrogen, halogen, cyano, difluoromethyl, trifluoromethyl, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 alkoxy, -$N(R^{10})(R^{11})$, C_3-C_5 cycloalkyl, or 4-6 membered heterocycloalkyl, wherein the C_1-C_6 alkyl is optionally substituted by one, two or three substituents selected from the group consisting of halogen, hydroxy, C_1-C_6 alkoxy, and -$N(R^{12})(R^{13})$,

provided that at least one of R^2 or R^5 is hydrogen;

R^3 is absent, hydrogen, halogen, C_1-C_6 alkyl, C_2-C_6 alkynyl, C_1-C_6 alkoxy, C_3-C_7 cycloalkyl, or 3-7 membered heterocycloalkyl, wherein the C_1-C_6 alkyl and the C_1-C_6 alkoxy are each optionally substituted by one, two or three R^{14} groups, and further wherein the C_3-C_7 cycloalkyl and the 3-7 membered heterocycloalkyl are each optionally substituted by one, two or three R^{15} groups;

Q is absent, O, S, or NR^9;

ring B is absent, C_3-C_{10} cycloalkyl, 3-10 membered heterocycloalkyl, C_6-C_{10} aryl, or 5-12 membered heteroaryl;

R^6 and R^8 are each independently absent, hydrogen, halogen, cyano, hydroxy, difluoromethyl, trifluoromethyl, C_1-C_3 alkyl, C_1-C_3 alkoxy, or C_3-C_5 cycloalkyl, wherein the C_1-C_3 alkyl is optionally substituted by hydroxy, difluoromethyl, trifluoromethyl, C_1-C_3 alkoxy, or C_3-C_5 cycloalkyl;

R^7 is



,


,


,


,


,


or


;

G is absent when the attachment point of R^7 on ring B is a nitrogen atom, and G is $-NR^{18}-$ when ring B is absent or when the attachment point of R^7 on ring B is a carbon atom;

R^9, R^{12} and R^{13} are each independently hydrogen or C_1-C_3 alkyl;

R^{10} and R^{11} are each independently hydrogen or C_1-C_6 alkyl; or R^{10} and R^{11} together with the nitrogen to which they are attached, may combine to form a 4-7 membered heterocycloalkyl ring, when R^{10} and R^{11} are each C_1-C_3 alkyl, wherein the 4-7 membered heterocycloalkyl ring formed is optionally substituted by one, two, three or four R^{15} groups;

each R^{14} is independently halogen, cyano, C_1-C_3 alkyl, hydroxy, C_1-C_6 alkoxy, $-N(R^{19})(R^{20})$, $-CON(R^{21})(R^{22})$, or 3-7 membered heterocycloalkyl, wherein the 3-7

membered heterocycloalkyl is optionally substituted by one, two, three or fourR^{15} groups;

each R^{15} is independently halogen, C_1-C_3 alkyl, hydroxy, C_1-C_6 alkoxy, $-NH_2$, $-NHCH_3$, or $-N(CH_3)_2$;

R^{16} and R^{17} are each independently hydrogen or C_1-C_6 alkyl, wherein the C_1-C_6 alkyl is optionally substituted by $-N(R^{23})(R^{24})$,

provided that R^{16} and R^{17} may form a C_3-C_5 cycloalkyl ring;

R^{18} is hydrogen or C_1-C_3 alkyl;

each R^{19}, R^{20}, R^{21}, R^{22}, R^{23}, and R^{24} is independently hydrogen or C_1-C_3 alkyl; and

m is 0, 1 or 2, provided that when ring B is absent, m is 2; or

a pharmaceutically acceptable salt thereof.

16. The compound or salt of claim 15 having formula (IIIa):



(IIIa)

wherein

n is 0, 1, or 2; and

p is 0, 1, or 2.

17. The compound or salt of claim 16, wherein n is 0.

18. The compound or salt of claims 15 or 16, wherein R^6 and R^8 are each independently hydrogen, halogen, C_1-C_3 alkyl, or C_1-C_3 alkoxy.

19. The compound or salt of claims 15 or 16, wherein R^6 is hydrogen, fluorine, methyl, or methoxy.

20. The compound or salt of claims 15 or 16, wherein R^6 is fluorine.

21. The compound or salt of claims 15 or 16, wherein R^8 is hydrogen, fluorine, or methyl.

22. The compound or salt of any of claims 16-21, having formula (IIIb):



(IIIb)

.

23. A compound, which is



,

or a pharmaceutically acceptable salt thereof.

24. A pharmaceutical composition comprising a compound of any of the preceding claims, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.

25. A combination of a compound of any of claims 1-23, or a pharmaceutically acceptable salt thereof, with an anti-tumor agent, for the treatment of cancer.

26. A method of treating abnormal cell growth in a mammal comprising administering to the mammal an amount of a compound of any of claims 1-23, or a pharmaceutically acceptable salt thereof, that is effective in treating abnormal cell growth.

What is claimed is:

1. A compound of formula (I):



(I)

wherein

R^1 is hydrogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 4-6 membered heterocycloalkyl, or 4-6 membered heteroaryl, wherein the C_1-C_6 alkyl is optionally substituted by one, two or three substituents selected from the group consisting of halogen, hydroxy, and C_1-C_3 alkoxy, further wherein the C_3-C_6 cycloalkyl, the 4-6 membered heterocycloalkyl, and the 4-6 membered heteroaryl are each independently optionally substituted by one, two or three substituents selected from the group consisting of C_1-C_3 alkyl, hydroxy, and C_1-C_3 alkoxy;

ring A is C_6-C_{10} aryl or 5-12 membered heteroaryl;

R^2 and R^5 are each independently absent, hydrogen, halogen, cyano, difluoromethyl, trifluoromethyl, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 alkoxy, -$N(R^{10})(R^{11})$, C_3-C_5 cycloalkyl, or 4-6 membered heterocycloalkyl, wherein the C_1-C_6 alkyl is optionally substituted by one, two or three substituents selected from the group consisting of halogen, hydroxy, C_1-C_6 alkoxy, and -$N(R^{12})(R^{13})$;

R^3 is absent, hydrogen, halogen, C_1-C_6 alkyl, C_2-C_6 alkynyl, C_1-C_6 alkoxy, C_3-C_7 cycloalkyl, or 3-7 membered heterocycloalkyl, wherein the C_1-C_6 alkyl and the C_1-C_6 alkoxy are each optionally substituted by one, two or three R^{14} groups, and further wherein the C_3-C_7 cycloalkyl and the 3-7 membered heterocycloalkyl are each optionally substituted by one, two or three R^{15} groups;

R^4 is absent, hydrogen, halogen, C_1-C_6 alkyl, or C_3-C_6 cycloalkyl,

wherein R^2 and R^3 or R^3 and R^4 may combine to form a C_5-C_7 cycloalkyl ring or a 5-7 membered heterocycloalkyl ring, further wherein the C_5-C_7 cycloalkyl ring and the 5-7 membered heterocycloalkyl ring are each independently optionally substituted by one, two or three R^{14} groups;

Q is absent, O, S, or NR^9;

ring B is absent, C_3-C_{10} cycloalkyl, 3-10 membered heterocycloalkyl, C_6-C_{10} aryl, or 5-12 membered heteroaryl;

R^6 and R^8 are each independently absent, hydrogen, halogen, cyano, hydroxy, difluoromethyl, trifluoromethyl, C_1-C_3 alkyl, C_1-C_3 alkoxy, or C_3-C_5 cycloalkyl, wherein the C_1-C_3 alkyl is optionally substituted by hydroxy, difluoromethyl, trifluoromethyl, C_1-C_3 alkoxy, or C_3-C_5 cycloalkyl;

R^7 is



,


,


,


,


,


or


;

G is absent when the attachment point of R^7 on ring B is a nitrogen atom, and G is $-NR^{18}-$ when ring B is absent or when the attachment point of R^7 on ring B is a carbon atom;

R^9, R^{12} and R^{13} are each independently hydrogen or C_1-C_3 alkyl;

R^{10} and R^{11} are each independently hydrogen or C_1-C_6 alkyl; or R^{10} and R^{11} together with the nitrogen to which they are attached, may combine to form a 4-7

membered heterocycloalkyl ring, when R^{10} and R^{11} are each C_1-C_3 alkyl, wherein the 4-7 membered heterocycloalkyl ring formed is optionally substituted by one, two, three or four R^{15} groups;

each R^{14} is independently halogen, cyano, C_1-C_3 alkyl, hydroxy, C_1-C_6 alkoxy, -$N(R^{19})(R^{20})$, -$CON(R^{21})(R^{22})$, or 3-7 membered heterocycloalkyl, wherein the 3-7 membered heterocycloalkyl is optionally substituted by one, two, three or four R^{15} groups;

each R^{15} is independently halogen, C_1-C_3 alkyl, hydroxy, C_1-C_6 alkoxy, -NH_2, -$NHCH_3$, or -$N(CH_3)_2$;

R^{16} and R^{17} are each independently hydrogen or C_1-C_6 alkyl, wherein the C_1-C_6 alkyl is optionally substituted by -$N(R^{23})(R^{24})$,

provided that R^{16} and R^{17} may form a C_3-C_5 cycloalkyl ring;

R^{18} is hydrogen or C_1-C_3 alkyl;

each R^{19}, R^{20}, R^{21}, R^{22}, R^{23}, and R^{24} is independently hydrogen or C_1-C_3 alkyl; and

m is 0, 1 or 2, provided that when ring B is absent, m is 2; or

a pharmaceutically acceptable salt thereof.

2. The compound or salt of claim 1, wherein R^1 is C_1-C_6 alkyl or C_3-C_6 cycloalkyl, wherein the C_1-C_6 alkyl is optionally substituted by hydroxy, further wherein the C_3-C_6 cycloalkyl is optionally substituted by C_1-C_3 alkyl.

3. The compound or salt of claim 1, wherein R^1 is methyl, ethyl, isopropyl, or tert-butyl.

4. The compound or salt of any of claims 1-3, wherein R^2 is hydrogen, methyl, difluoromethyl, or methoxy.

5. The compound or salt of any of claims 1-3, wherein R^5 is hydrogen, C_1-C_6 alkyl, or C_1-C_6 alkoxy.

6. The compound or salt of any of claims 1-3, wherein R^5 is hydrogen, methyl, or methoxy.

7. The compound or salt of any of claims 1-3, wherein R^3 is C_1-C_6 alkyl or 3-7 membered heterocycloalkyl, wherein the C_1-C_6 alkyl is optionally substituted by one or two R^{14} groups, further wherein the 3-7 membered heterocycloalkyl is optionally substituted by C_1-C_3 alkyl.

8. The compound or salt of any of claims 1-3, wherein R^3 is methyl.

9. The compound or salt of claim 1, wherein Q is absent.

10. The compound or salt of claim 1, wherein Q is O.

11. The compound or salt of claim 1, wherein Q is NR^9.

12. The compound or salt of claim 1, wherein m is 0.

13. The compound or salt of any one of claims 1-3, wherein ring B is 3-10 membered heterocycloalkyl.

14. The compound or salt of any one of claims 1-3 and 9-12, having formula (II):



(II)

wherein

X is CH or N;

W is CR^2 or N,

provided that one of X and W is N and X and W cannot both be N, further provided that when W is CR^2, at least one of R^2 and R^5 is hydrogen;

R^1 is hydrogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 4-6 membered heterocycloalkyl, or 4-6 membered heteroaryl, wherein the C_1-C_6 alkyl is optionally substituted by one, two or three substituents selected from the group consisting of halogen, hydroxy, and C_1-C_3 alkoxy, further wherein the C_3-C_6 cycloalkyl, the 4-6 membered heterocycloalkyl, and the 4-6 membered heteroaryl are each independently optionally substituted by one, two or three substituents selected from the group consisting of C_1-C_3 alkyl, hydroxy, and C_1-C_3 alkoxy;

R^2 and R^5 are each independently hydrogen, halogen, cyano, difluoromethyl, trifluoromethyl, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 alkoxy, -N(R^{10})(R^{11}), C_3-C_5 cycloalkyl, or 4-6 membered heterocycloalkyl, wherein the C_1-C_6 alkyl is optionally substituted by one, two or three substituents selected from the group consisting of halogen, hydroxy, C_1-C_6 alkoxy, and -N(R^{12})(R^{13});

R^3 is hydrogen, halogen, C_1-C_6 alkyl, C_2-C_6 alkynyl, C_1-C_6 alkoxy, C_3-C_7 cycloalkyl, or 3-7 membered heterocycloalkyl, wherein the C_1-C_6 alkyl and the C_1-C_6 alkoxy are each optionally substituted by one, two or three R^{14} groups, and further wherein the C_3-C_7 cycloalkyl and the 3-7 membered heterocycloalkyl are each optionally substituted by one, two or three R^{15} groups;

Q is absent, O, S, or NR^9;

ring B is absent, C_3-C_{10} cycloalkyl, 3-10 membered heterocycloalkyl, C_6-C_{10} aryl, or 5-12 membered heteroaryl;

R^6 and R^8 are each independently absent, hydrogen, halogen, cyano, hydroxy, difluoromethyl, trifluoromethyl, C_1-C_3 alkyl, C_1-C_3 alkoxy, or C_3-C_5 cycloalkyl, wherein the C_1-C_3 alkyl is optionally substituted by hydroxy, difluoromethyl, trifluoromethyl, C_1-C_3 alkoxy, or C_3-C_5 cycloalkyl;

R^7 is



,



,



,



,



,



or



;

G is absent when the attachment point of R^7 on ring B is a nitrogen atom, and G is $-NR^{18}-$ when ring B is absent or when the attachment point of R^7 on ring B is a carbon atom;

R^9, R^{12} and R^{13} are each independently hydrogen or C_1-C_3 alkyl;

R^{10} and R^{11} are each independently hydrogen or C_1-C_6 alkyl; or R^{10} and R^{11} together with the nitrogen to which they are attached, may combine to form a 4-7 membered heterocycloalkyl ring, when R^{10} and R^{11} are each C_1-C_3 alkyl, wherein the 4-7 membered heterocycloalkyl ring formed is optionally substituted by one, two, three or four R^{15} groups;

each R^{14} is independently halogen, cyano, C_1-C_3 alkyl, hydroxy, C_1-C_6 alkoxy, $-N(R^{19})(R^{20})$, $-CON(R^{21})(R^{22})$, or 3-7 membered heterocycloalkyl, wherein the 3-7 membered heterocycloalkyl is optionally substituted by one, two, three or four R^{15} groups;

each R^{15} is independently halogen, C_1-C_3 alkyl, hydroxy, C_1-C_6 alkoxy, $-NH_2$, $-NHCH_3$, or $-N(CH_3)_2$;

R^{16} and R^{17} are each independently hydrogen or C_1-C_6 alkyl, wherein the C_1-C_6 alkyl is optionally substituted by $-N(R^{23})(R^{24})$,

provided that R^{16} and R^{17} may form a C_3-C_5 cycloalkyl ring;

R^{18} is hydrogen or C_1-C_3 alkyl;

each R^{19}, R^{20}, R^{21}, R^{22}, R^{23}, and R^{24} is independently hydrogen or C_1-C_3 alkyl; and

m is 0, 1 or 2, provided that when ring B is absent, m is 2.

15. The compound or salt of any one of claims 1-3 and 9-12, having formula (III):



(III)

wherein

R^1 is hydrogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 4-6 membered heterocycloalkyl, or 4-6 membered heteroaryl, wherein the C_1-C_6 alkyl is optionally substituted by one, two or three substituents selected from the group consisting of halogen, hydroxy, and C_1-C_3 alkoxy, further wherein the C_3-C_6 cycloalkyl, the 4-6 membered heterocycloalkyl, and the 4-6 membered heteroaryl are each independently optionally substituted by one, two or three substituents selected from the group consisting of C_1-C_3 alkyl, hydroxy, and C_1-C_3 alkoxy;

R^2 and R^5 are each independently hydrogen, halogen, cyano, difluoromethyl, trifluoromethyl, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 alkoxy, -N(R^{10})(R^{11}), C_3-C_5 cycloalkyl, or 4-6 membered heterocycloalkyl, wherein the C_1-C_6 alkyl is optionally substituted by one, two or three substituents selected from the group consisting of halogen, hydroxy, C_1-C_6 alkoxy, and -N(R^{12})(R^{13}),

provided that at least one of R^2 or R^5 is hydrogen;

R^3 is hydrogen, halogen, C_1-C_6 alkyl, C_2-C_6 alkynyl, C_1-C_6 alkoxy, C_3-C_7 cycloalkyl, or 3-7 membered heterocycloalkyl, wherein the C_1-C_6 alkyl and the C_1-C_6 alkoxy are each optionally substituted by one, two or three R^{14} groups, and further wherein the C_3-C_7 cycloalkyl and the 3-7 membered heterocycloalkyl are each optionally substituted by one, two or three R^{15} groups;

Q is absent, O, S, or NR^9;

ring B is absent, C_3-C_{10} cycloalkyl, 3-10 membered heterocycloalkyl, C_6-C_{10} aryl, or 5-12 membered heteroaryl;

R^6 and R^8 are each independently absent, hydrogen, halogen, cyano, hydroxy, difluoromethyl, trifluoromethyl, C_1-C_3 alkyl, C_1-C_3 alkoxy, or C_3-C_5 cycloalkyl, wherein the C_1-C_3 alkyl is optionally substituted by hydroxy, difluoromethyl, trifluoromethyl, C_1-C_3 alkoxy, or C_3-C_5 cycloalkyl;

R^7 is


,

,

,

,

,

or

;

G is absent when the attachment point of R^7 on ring B is a nitrogen atom, and G is -NR^{18}- when ring B is absent or when the attachment point of R^7 on ring B is a carbon atom;

R^9, R^{12} and R^{13} are each independently hydrogen or C_1-C_3 alkyl;

R^{10} and R^{11} are each independently hydrogen or C_1-C_6 alkyl; or R^{10} and R^{11} together with the nitrogen to which they are attached, may combine to form a 4-7 membered heterocycloalkyl ring, when R^{10} and R^{11} are each C_1-C_3 alkyl, wherein the 4-7 membered heterocycloalkyl ring formed is optionally substituted by one, two, three or four R^{15} groups;

each R^{14} is independently halogen, cyano, C_1-C_3 alkyl, hydroxy, C_1-C_6 alkoxy, -$N(R^{19})(R^{20})$, -$CON(R^{21})(R^{22})$, or 3-7 membered heterocycloalkyl, wherein the 3-7

membered heterocycloalkyl is optionally substituted by one, two, three or fourR^{15} groups;

each R^{15} is independently halogen, C_1-C_3 alkyl, hydroxy, C_1-C_6 alkoxy, $-NH_2$, $-NHCH_3$, or $-N(CH_3)_2$;

R^{16} and R^{17} are each independently hydrogen or C_1-C_6 alkyl, wherein the C_1-C_6 alkyl is optionally substituted by $-N(R^{23})(R^{24})$,

provided that R^{16} and R^{17} may form a C_3-C_5 cycloalkyl ring;

R^{18} is hydrogen or C_1-C_3 alkyl;

each R^{19}, R^{20}, R^{21}, R^{22}, R^{23}, and R^{24} is independently hydrogen or C_1-C_3 alkyl; and

m is 0, 1 or 2, provided that when ring B is absent, m is 2.

16. The compound or salt of claim 15 having formula (IIIa):



(IIIa)

wherein

n is 0, 1, or 2; and

p is 0, 1, or 2.

17. The compound or salt of claim 16, wherein n is 0.

18. The compound or salt of claim 16, wherein R^6 and R^8 are each independently hydrogen, halogen, C_1-C_3 alkyl, or C_1-C_3 alkoxy.

19. The compound or salt of claim 16, wherein R^6 is hydrogen, fluorine, methyl, or methoxy.

20. The compound or salt of claim 16, wherein R^6 is fluorine.

21. The compound or salt of claim 16, wherein R^8 is hydrogen, fluorine, or methyl.

22. The compound or salt of claim 16, having formula (IIIb):



(IIIb)

.

23. A compound, which is



,

or a pharmaceutically acceptable salt thereof.

24. A pharmaceutical composition comprising a compound of any one of claims 1-3, 9-12 and 23, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.

25. A combination of a compound of any one of claims 1-3, 9-12 and 23, or a pharmaceutically acceptable salt thereof, with an anti-tumor agent, for the treatment of cancer.

26. A compound of any one of claims 1-3, 9-12 and 23, or a pharmaceutically acceptable salt thereof, that is effective in treating abnormal cell growth, for use in the treatment of abnormal cell growth in a mammal.